www.bewusstseinszustände.de
 

Literaturverzeichnis

Adamson S, Metzner R: The Nature of the MDMA Experience and its Role in Healing, Psychotherapy, and Spiritual Practice. Revision 1988, 10 (4): 59-72

Baggot M, Mendelson J: Does MDMA Cause Brain Damage? In: Holland J (ed.): Ecstasy: The Complete Guide. Rochester, Vermont: Park Street Press 2001

Collin M, Godfrey J: Im Rausch der Sinne. St. Andrä/Wörden: Hannibal 1998

Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX: 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology. 2000, 23: 388-95

Gasser P: Die psycholytische Psychotherapie in der Schweiz von 1988-1993. Eine katamnestische Erhebung. Schweizer Archiv für Neurologie und Psychiatrie 1997, 147: 59-65

Gouzoulis E, von Bardeleben U, Rupp A, Kovar K-A, Hermle L: Neuroendocrine and cardiovascular effects of MDE in healthy volunteers.
Neuropsychopharmacology. 1993, 8: 187-93

Gouzoulis-Mayfrank E, Daumann J, Sass H: Neurotoxische Langzeitschäden bei Ecstasy (MDMA)-Konsumenten. Überblick uber den aktuellen Wissensstand. Nervenarzt 2002; 73: 405-21

Gouzoulis-Mayfrank E, Hermle L, Kovar KA, Sass H: Die Entaktogene „Ecstasy“ (MDMA), „Eve“ (MDE) und andere ringsubstituierte Methamphetaminderivate. Eine neue Stoffklasse unter den illegalen Designerdrogen ? Nervenarzt 1996, 67:369-380

Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning,C, Thelen B, Spitzer M, Kovar KA, Hermle L, Bull U, Sass H. Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers. Neuropsychopharmacology 1999a, 20: 565-581

Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, Hermle L, Spitzer M, Sass H. Psychopathological, Neuroendocrine and autonomic Effects of 3,4-Methylenedioxyethylamphetamine (MDE), Psilocybin and d-Methamphetamine in Healthy Volunteers. Psychopharmalology (Berl) 1999b, 142: 41-50

Hasler F, Bourquin D, Brenneisen R, Bär T, Vollenweider FX: Determination of psilocybin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharmaceutica Acta Helvetiae 1997, 72: 175-184

Hermle L, Funfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach R-A, Spitzer M: Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research.
Biol Psychiatry. 1992, 32: 976-91

Hermle L, Gouzoulis-Mayfrank E, Spitzer M: Halluzinogen-induzierte psychische Storungen. Subjektives Erleben, Psychopathologie und Differentialdiagnose.
Fortschr Neurol Psychiatr. 1996, 64: 482-91

Hermle L, Spitzer M, Borchardt D, Kovar K-A, Gouzoulis E: Psychological Effects of3,4-Methylendioxyethamphetamine (MDE, “Eve”) in Normal Subjects: Are Entactogens a New Class of Psychoactive Agents? Neuropsychopharmacology 1993, 8: 171-176

Holzmann PP. Bestimmung von Psilocybin-Metaboliten im Humanplasma und –urin. Tübingen: Phil. Dissertation 1995.

McCann UD, Szabo Z, Scheffel U, Dannals RF Ricaurte GA: Positron emission tomographic evidence of toxic effect of MDMA („Ecstasy“) on brain serotonin neurons in human beings. Lancet 1998, 352: 1433-1437.

Nichols DE: Differences Between the Mechanisms of Action of MDMA, MBDB, and the Classic Hallucinogens: Identification of a New Therapeutic Class – Entactogens. Journal of Psychoactive Drugs 1986, 18: 305-313

Peroutka SJ, Newman H, Harris H: Subjective effects of 3,4-Methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988, 1: 273-277.

Ricaurte, GA, Forno LS, Wilson MA, Delanney LE, Irwin I, Molliver ME, Langston JW: 3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. Journal of the American Medical Association 1988, 260: 51-55.

Schlichting M: DieBedeutung der Halluzinogenforschung für die klinische Psychiatrie und Psychotherapie. Göttingen: Med. Dissertation 1997

Schneider U, Lewecke FM, Sternemann U, Weber MM, Emrich HM: Visual 3D Illusion: A Systems-Theoretical Approach to Psychosis. European Archives of Psychiatry and Clinical Neuroscience 1999, 246:256-260

Schreckenberger,-M, Gouzoulis-Mayfrank,-E, Sabri,-O, Arning,-C, Tuttass,-T, Schulz,-G, Kaiser,-H-J, Wagenknecht,-G, Sass,-H, Bull,-U: Untersuchungen zum Einfluss von "Ecstasy" auf den zerebralen Glukosemetabolismus: eine 18-FDG-PET-Studie. Nuklearmedizin. 1998, 37: 262-7

Spitzer M, Franke B, Walter H, Buechler J, Wunderlich A-P, Schwab M, Kovar K-A, Hermle L, Gron G: Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans.
Neuropharmacology. 2001, 41: 263-71

Spitzer M, Thimm M, Hermle L, Holzmann P, Kovar K-A, Heimann H, Gouzoulis-Mayfrank E, Kischka U, Schneider F. Increased activation of indirect semantic associations under psilocybin. Biol. Psychiatry 1996, 39: 1055-1057.

Styk J: Rückblick auf die letzten sieben Jahre der Schweizerischen Ärztegesellschaft für Psycholytische Therapie (SÄPT). In: Dittrich A, Hofmann A, Leuner H (Hrsg.): Welten des Bewusstseins. Vol. 4. Berlin: Verlag für Wissenschaft und Bildung 1994, S. 149-154.

Thomasius R (Hrsg.): Ecstasy. Stuttgart: Wissenschaftliche Verlagsgesellschaft 2000

Vollenweider FX, Leenders KL, Scharfetter C, Maguiere P Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 1997, 16. 357-372.

Vollenweider FX, Leenders KL, Scharfetter C, Antonioni A, Maguire P, Missimer J, Angst J: Metabolic Hyperfrontality and Psychopathology in the Ketamine Model of Psychosis Using Positron Emission Tomography (PET) and [18 F] Fluorodeoxyglucose (FDG). European Neuropsychopharmacology 1997; 7: 9-24

Vollenweider FX, Vollenweider-Scherpenhuysen MFI, Babler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via serotonin-2 agonist action. Neuroreport 1998; 9: 3897-3902.

Vollenweider FX, Gamma A, Liechti M, Huber T: Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers. Neuropsychopharmacology. 1998; 19: 241-51

Vollenweider FX, Gamma A, Liechti M, Huber T: Is a single dose of MDMA harmless? Neuropsychopharmacology. 1999; 21: 598-600

Vollenweider FX, Liechti ME, Gamma A, Greer G, Geyer M: Acute psychological and neurophysiological effects of MDMA in humans. Journal of Psychoactive Drugs. 2002; 34: 171-84

Vollenweider FX, Geyer MA: A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Research Bulletin 2001; 56: 495-507